PIPERACILLIN AND TAZOBACTAM FOR INJECTION POWDER FOR SOLUTION

Страна: Канада

мова: англійська

Джерело: Health Canada

Активний інгредієнт:

PIPERACILLIN (PIPERACILLIN SODIUM); TAZOBACTAM (TAZOBACTAM SODIUM)

Доступна з:

FRESENIUS KABI CANADA LTD

Код атс:

J01CR05

ІПН (Міжнародна Ім'я):

PIPERACILLIN AND BETA-LACTAMASE INHIBITOR

Дозування:

12G; 1.5G

Фармацевтична форма:

POWDER FOR SOLUTION

Склад:

PIPERACILLIN (PIPERACILLIN SODIUM) 12G; TAZOBACTAM (TAZOBACTAM SODIUM) 1.5G

Адміністрація маршрут:

INTRAVENOUS

Одиниць в упаковці:

100

Тип рецепту:

Prescription

Терапевтична области:

EXTENDED-SPECTRUM PENICILLINS

Огляд продуктів:

Active ingredient group (AIG) number: 0225919007; AHFS:

Статус Авторизація:

APPROVED

Дата Авторизація:

2017-07-07

Характеристики продукта

_ _
_Piperacillin and Tazobactam for Injection _
_Page 1 of 43_
PRODUCT MONOGRAPH
INCUDING PATIENT MEDICATION INFORMATION
PR
PIPERACILLIN AND TAZOBACTAM FOR INJECTION
Piperacillin Sodium/Tazobactam Sodium
Lyophilized Powder for Injection
For Intravenous Use Only
MANUFACTURER’S STANDARD
PIPERACILLIN 12 G (AS PIPERACILLIN SODIUM) AND TAZOBACTAM 1.5 G (AS
TAZOBACTAM SODIUM) PER VIAL
PIPERACILLIN 36 G (AS PIPERACILLIN SODIUM) AND TAZOBACTAM 4.5 G (AS
TAZOBACTAM SODIUM) PER VIAL
Antibiotic/β-lactamase Inhibitor
FRESENIUS KABI CANADA LTD.
165 Galaxy Blvd, Suite 100
Toronto, Ontario
M9W 0C8
Date of Revision:
November 18, 2020
Submission Control No.: 246054
_ _
_Piperacillin and Tazobactam for Injection _
_Page 2 of 43_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................5
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
....................................................................................................8
DRUG INTERACTIONS
..................................................................................................12
DOSAGE AND ADMINISTRATION
..............................................................................14
OVERDOSAGE
................................................................................................................18
ACTION AND CLINICAL PHARMACOLOGY
............................................................19
STORAGE AND STABILITY
..........................................................................................21
SPECIAL HANDLING INSTRUCTIONS
......................................................